Net profit of Pfizer declined 13.73% to Rs 129.98 crore in the quarter ended December 2023 as against Rs 150.66 crore during the previous quarter ended December 2022. Sales declined 13.15% to Rs 539.97 crore in the quarter ended December 2023 as against Rs 621.75 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales539.97621.75 -13 OPM %28.2532.72 - PBDT185.54227.02 -18 PBT167.99200.68 -16 NP129.98150.66 -14 Powered by Capital Market - Live News

Pfizer will hold a meeting of the Board of Directors of the Company on 9 February 2024.Powered by Capital Market - Live News

Pfizer and Glenmark Pharmaceuticals (Glenmark) have joined hands to launch abrocitinib, a first of its kind oral advanced systemic treatment for moderate‐to‐severe atopic dermatitis (AD), in India. Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies. When launched in India, it will be co‐marketed under the brand names JABRYUS� and CIBINQO� by Glenmark and Pfizer respectively. This collaboration combines the expertise of the companies to offer a groundbreaking treatment for moderate‐to‐severe AD, with improved efficacy and oral convenience to patients. Abrocitinib (CIBINQO) is available in over 35 markets globally, including the U.S., Japan, and China.   Atopic dermatitis is a chronic skin disease characterized by inflammation of the skin and skin barrier defects 1,2. The persistent itching associated with moderate‐to‐severe AD disrupts daily life, impacting social interactions, work productivity, and overall well‐being. Abrocitinib, a Janus kinase 1 (JAK1) inhibitor, providesrapid itch relief, sustained disease control, and a vastly improved quality of life for patientPowered by Capital Market - Live News

Pfizer has appointed Amit Agarwal (DIN: 10465938) as an Additional Director (Whole-time Director) of the Company, designated as Executive Director � Finance & Chief Financial Officer for a period of 5 years with effect from 26 February 2024.Powered by Capital Market - Live News

Pfizer has appointed Aditi Mehta as Category Lead, Vaccines effective 01 December 2023. Accordingly, Ms. Aditi Mehta shall be a Senior Management Personnel effective the said datePowered by Capital Market - Live News